Increased treatment failure after 3-days’ courses of nitrofurantoin and trimethoprim for urinary tract infections in women: a population-based retrospective cohort study using the...

Por Goettsch, Wim G, Janknegt, Rob, Herings, Ron M C
Publicado em 2004

Why we should have more collaboration on HTA in Europe: the example of sofosbuvir

Por Schelleman, Hedi, Dupree, Rudy, Kristensen, Finn B, Goettsch, Wim
Publicado no J Pharm Policy Pract (2015)

Companies’ Health Technology Assessment Strategies and Practices in Australia, Canada, England, France, Germany, Italy and Spain: An Industry Metrics Study

Por Wang, Ting, McAuslane, Neil, Liberti, Lawrence, Gardarsdottir, Helga, Goettsch, Wim, Leufkens, Hubert
Publicado no Front Pharmacol (2020)

Use of Social Media in the Assessment of Relative Effectiveness: Explorative Review With Examples From Oncology

Por Kalf, Rachel RJ, Makady, Amr, ten Ham, Renske MT, Meijboom, Kim, Goettsch, Wim G
Publicado no JMIR Cancer (2018)

Use of medicine pricing and reimbursement policies for universal health coverage in Indonesia

Por Wasir, Riswandy, Irawati, Sylvi, Makady, Amr, Postma, Maarten, Goettsch, Wim, Buskens, Erik, Feenstra, Talitha
Publicado no PLoS One (2019)

The implementation of HTA in medicine pricing and reimbursement policies in Indonesia: Insights from multiple stakeholders

Por Wasir, Riswandy, Irawati, Sylvi, Makady, Amr, Postma, Maarten, Goettsch, Wim, Feenstra, Talitha, Buskens, Erik
Publicado no PLoS One (2019)

Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis

Por A Vreman, Rick, F Broekhoff, Thomas, GM Leufkens, Hubert, K Mantel-Teeuwisse, Aukje, G Goettsch, Wim
Publicado no Int J Environ Res Public Health (2020)

Bridging the gap: Can International Consortium of Health Outcomes Measurement standard sets align outcomes accepted for regulatory and health technology assessment decision‐making...

Por Kalf, Rachel R. J., Vreman, Rick A., Delnoij, Diana M.J., Bouvy, Marcel L., Goettsch, Wim G.
Publicado no Pharmacol Res Perspect (2021)

The impact of quality-of-life data in relative effectiveness assessments of new anti-cancer drugs in European countries

Por Kleijnen, Sarah, Leonardo Alves, Teresa, Meijboom, Kim, Lipska, Iga, De Boer, Anthonius, Leufkens, Hubertus G., Goettsch, Wim G.
Publicado no Qual Life Res (2017)

Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia

Por Vreman, Rick A., Geenen, Joost W., Hövels, Anke M., Goettsch, Wim G., Leufkens, Hubert G. M., Al, Maiwenn J.
Publicado no Appl Health Econ Health Policy (2019)

The Application and Implications of Novel Deterministic Sensitivity Analysis Methods

Por Vreman, Rick A., Geenen, Joost W., Knies, Saskia, Mantel-Teeuwisse, Aukje K., Leufkens, Hubert G. M., Goettsch, Wim G.
Publicado no Pharmacoeconomics (2020)

Social media as a tool for assessing patient perspectives on quality of life in metastatic melanoma: a feasibility study

Por Makady, Amr, Kalf, Rachel R. J., Ryll, Bettina, Spurrier, Gilliosa, de Boer, Anthonius, Hillege, Hans, Klungel, Olaf H., Goettsch, Wim
Publicado no Health Qual Life Outcomes (2018)

Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies

Por Makady, Amr, van Veelen, Ard, Jonsson, Páll, Moseley, Owen, D’Andon, Anne, de Boer, Anthonius, Hillege, Hans, Klungel, Olaf, Goettsch, Wim
Publicado no Pharmacoeconomics (2017)

Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and Europe

Por Vreman, Rick A., Naci, Huseyin, Goettsch, Wim G., Mantel‐Teeuwisse, Aukje K., Schneeweiss, Sebastian G., Leufkens, Hubert G. M., Kesselheim, Aaron S.
Publicado no Clin Pharmacol Ther (2020)

Weighing of Evidence by Health Technology Assessment Bodies: Retrospective Study of Reimbursement Recommendations for Conditionally Approved Drugs

Por Vreman, Rick A., Bouvy, Jacoline C., Bloem, Lourens T., Hövels, Anke M., Mantel‐Teeuwisse, Aukje K., Leufkens, Hubert G.M., Goettsch, Wim G.
Publicado no Clin Pharmacol Ther (2018)

The Relationship between Antimicrobial Use and Antimicrobial Resistance in Europe

Por Bronzwaer, Stef L.A.M., Cars, Otto, Buchholz, Udo, Mölstad, Sigvard, Goettsch, Wim, Veldhuijzen, Irene K., Kool, Jacob L., Sprenger, Marc J.W., Degener, John E.
Publicado em 2002

Efficacy gap between phase II and subsequent phase III studies in oncology

Por Vreman, Rick A., Belitser, Svetlana V., Mota, Ana T.M., Hövels, Anke M., Goettsch, Wim G., Roes, Kit C.B., Leufkens, Hubert G.M., Mantel‐Teeuwisse, Aukje K.
Publicado no Br J Clin Pharmacol (2020)

Inappropriate initial treatment of secondary intra-abdominal infections leads to increased risk of clinical failure and costs

Por Sturkenboom, Miriam C J M, Goettsch, Wim G, Picelli, Gino, in ‘t Veld, Bas, Yin, Don D, de Jong, Romy B, Go, Peter M N Y H, Herings, Ron M C
Publicado em 2005

Good practices for real‐world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR‐ISPE Special Task Force on real‐world evidence in hea...

Por Berger, Marc L., Sox, Harold, Willke, Richard J., Brixner, Diana L., Eichler, Hans‐Georg, Goettsch, Wim, Madigan, David, Makady, Amr, Schneeweiss, Sebastian, Tarricone, Rosanna, Wang, Shirley V., Watkins, John, Daniel Mullins, C.
Publicado no Pharmacoepidemiol Drug Saf (2017)